首页> 外文期刊>BMC Oral Health >Small-diameter titanium grade IV and titanium-zirconium implants in edentulous mandibles: five-year results from a double-blind, randomized controlled trial
【24h】

Small-diameter titanium grade IV and titanium-zirconium implants in edentulous mandibles: five-year results from a double-blind, randomized controlled trial

机译:无牙颌中的小直径IV级钛和钛锆植入物:一项双盲,随机对照试验的五年结果

获取原文

摘要

Background The aim of this study was to compare the 5-year survival and success rates of 3.3?mm dental implants either made from titanium-zirconium (TiZr) alloy or from Grade IV titanium (Ti Grade IV) in mandibular implant-based removable overdentures. Methods The core study had a follow-up period of 36?months and was designed as a randomized, controlled, double-blind, split-mouth multicenter clinical trial. Patients with edentulous mandibles received two Straumann Bone Level implants (diameter 3.3?mm, SLActive?), one of TiZr (test) and one of Ti Grade IV (control), in the interforaminal region. This follow-up study recruited patients from the core study and evaluated the plaque and sulcus bleeding indices, radiographic crestal bone level, as well as implant survival and success 60?months after implant placement. Results Of the 91 patients who initially received implants, 75 completed the 36?month follow-up and 49 were available for the 60?month examination. Two patients were excluded so that a total of 47 patients with an average age of 72?±?8?years were analysed. The characteristics and 36-month performance of the present study cohort did not differ from the non-included initial participants (p?>?0.05). In the period since the 36-month follow-up examination, no implant was lost. The cumulative implant survival rate was 98.9?% for the TiZr group and 97.8?% for the Ti Grade IV group. Crestal bone level changes at 60?months were not different in the test and control group (TiZr ?0.60?±?0.69?mm and Ti Grade IV ?0.61?±?0.83?mm; p?=?0.96). The cumulative implant success rate after 60?months was 95.8 and 92.6?% for TiZr and Ti Grade IV, respectively. Conclusions After 60?months, the positive outcomes of the 36?month results for TiZr and Ti Grade IV implants were confirmed, with no significant differences with regard to crestal bone level change, clinical parameters and survival or success rates. TiZr implants performed equally well compared to conventional Ti Grade IV 3.3?mm diameter-reduced implants for mandibular removable overdentures. Trial registration Registered on www.clinicaltrials.gov: NCT01878331
机译:背景研究的目的是比较由钛锆(TiZr)合金或IV级钛(IV级)制成的3.3?mm牙种植体在下颌种植体可摘覆盖义齿中的5年生存率和成功率。 。方法核心研究随访期为36个月,被设计为一项随机,对照,双盲,裂口多中心临床试验。下颌无牙的患者在椎间孔区域接受了两种Straumann骨水平植入物(直径3.3?mm,SLActive?),一种是TiZr(测试),另一种是IV级钛(对照)。这项随访研究从核心研究中招募了患者,并评估了种植体放置60个月后的斑块和沟出血指数,影像学的颅骨水平以及种植体的存活率和成功率。结果在最初接受植入物的91例患者中,有75例完成了36个月的随访,其中49例可以进行60个月的检查。排除了两名患者,因此对总共47例平均年龄为72±8岁的患者进行了分析。本研究队列的特征和36个月的表现与未包括在内的初始参与者没有差异(p≥0.05)。自从36个月的随访检查以来,没有植入物丢失。 TiZr组的累积植入物存活率为98.9%,而Ti级IV组的累积植入物存活率为97.8%。试验组和对照组在60个月时的骨质水平变化无差异(TiZr≤0.60≤±≤0.69≤mm和Ti级IV≤0.61≤±0.83≤mm; p≤0.96)。 TiZr和Ti IV级在60个月后的累计植入成功率分别为95.8%和92.6%。结论60个月后,TiZr和Ti IV级植入物的36个月结果得到了肯定的结果,在cre骨水平变化,临床参数以及生存或成功率方面无显着差异。 TiZr种植体与用于下颌可摘覆盖义齿的常规Ti IV级,直径减小了3.3?mm的种植体相比,表现同样出色。试用注册在www.clinicaltrials.gov上注册:NCT01878331

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号